Shared on03 Oct 25Fair value Increased 1.85%
The consensus analyst price target for iRhythm Technologies has increased modestly from $182.62 to $186.00. Analysts cite positive physician feedback and expected market expansion as key drivers for their outlook.
Shared on27 Aug 25Fair value Increased 2.16%
The consensus analyst price target for iRhythm Technologies has increased to $181.62, driven by a proposed CMS reimbursement boost, robust MyZio app growth, management’s confidence in market share gains, and progress on FDA remediation, reflecting improved fundamentals and growth visibility. Analyst Commentary Proposed CMS Physician Fee Schedule includes a low-single digit reimbursement boost for mobile cardiac telemetry, reversing previous larger cuts and providing greater payment visibility.
Shared on02 Aug 25Fair value Increased 22%
The upward revision in iRhythm Technologies’ consensus price target reflects improved net profit margin and a substantially lower future P/E multiple, raising the fair value estimate from $146.83 to $159.83. What's in the News iRhythm Technologies issued full-year 2025 revenue guidance of $720–$730 million.